Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Patient characteristics

From: Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial

  Intervention group Control group
  (total n = 1154) (total n = 1457)
Age (y): Median (min, max) 72 (18,100) 72 (18,102)
Male: n (%) 534 (46) 688 (47)
Length of stay (days): Median (min, max) 4 (0,79) 5 (0,133)
VTE risk factors: n (%)   
Congestive heart failure 140 (12) 166 (11)
Acute respiratory disease 181 (16) 133 (9)
Acute ischemic stroke 68 (6) 92 (6)
Cancer 93 (8) 172 (12)
Sepsis 145 (13) 111 (8)
Acute neurological disease 24 (2) 13 (1)
Inflammatory bowel disease 23 (2) 25 (2)
Prior VTE 26 (2) 22 (2)
Immobility 637 (55) 806 (55)
Bleeding risk factors: n (%)   
Acute bleeding 64 (6) 134 (9)
At risk for bleeding 116 (10) 90 (6)
Recent bleeding 22 (2) 5 (0)
Coagulopathy 93 (8) 185 (13)
Thrombocytopenia 36 (3) 50 (3)
VTE risk profile: n (%)
At risk for VTE without risk of bleeding 436 (38) 465 (32)
At risk for VTE with risk of bleeding 132 (11) 167 (11)
Not at risk for VTE 586 (51) 825 (57)
  1. All percentages use total number of eligible patients as denominator.
  2. VTE = venous thromboembolism.